NapaJen
NapaJen Pharma is a biopharmaceutical research and development company focused on creating nucleic acid medicines using proprietary technology. They aim to deliver nucleic acid drugs to immune cells, significantly shorten drug development periods, and contribute to new drug creation through collaborations with other pharmaceutical companies.
Industries
Nr. of Employees
small (1-50)
NapaJen
Seattle, Washington, United States, North America
Products
NJA-730 (RNAi therapeutic candidate)
An RNAi-based therapeutic candidate developed using a cell-specific oligonucleotide delivery platform that progressed to a Phase I clinical trial in Australia.
Cell-specific oligonucleotide drug delivery platform
A technology platform for loading and delivering different oligonucleotide drugs to specified immune cell types to achieve precision immunomodulation.
NJA-730 (RNAi therapeutic candidate)
An RNAi-based therapeutic candidate developed using a cell-specific oligonucleotide delivery platform that progressed to a Phase I clinical trial in Australia.
Cell-specific oligonucleotide drug delivery platform
A technology platform for loading and delivering different oligonucleotide drugs to specified immune cell types to achieve precision immunomodulation.
Services
Partnerships for co-development of nucleic acid therapeutics
Collaborative services from early target selection through application of cell-targeted delivery technology to partner candidates; includes technology-sharing and joint research projects.
Preclinical development services for oligonucleotide therapeutics
Provision of preclinical evaluation and demonstration of targeted immunomodulatory effects using cell-targeted oligonucleotide delivery platforms.
Partnerships for co-development of nucleic acid therapeutics
Collaborative services from early target selection through application of cell-targeted delivery technology to partner candidates; includes technology-sharing and joint research projects.
Preclinical development services for oligonucleotide therapeutics
Provision of preclinical evaluation and demonstration of targeted immunomodulatory effects using cell-targeted oligonucleotide delivery platforms.
Expertise Areas
- Nucleic acid (oligonucleotide/RNAi) therapeutic development
- Cell-targeted drug delivery
- Immunotherapy and immune-cell modulation
- Preclinical to early clinical translation
Key Technologies
- Oligonucleotide therapeutics (RNAi)
- Cell-specific drug delivery platforms
- Dendritic cell targeting/modulation
- Dectin-1 receptor-mediated delivery